Serina Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Serina Therapeutics
SER Stock   2.44  0.08  3.17%   
Serina Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Serina Therapeutics' valuation are provided below:
Gross Profit
-12 M
Market Capitalization
26.9 M
Enterprise Value Revenue
211.2797
Revenue
116 K
Earnings Share
(1.87)
There are over one hundred nineteen available fundamental trend indicators for Serina Therapeutics, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Serina Therapeutics' current fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 12/24/2025, Market Cap is likely to drop to about 84.9 M. In addition to that, Enterprise Value is likely to drop to about 84.4 M

Serina Therapeutics Total Revenue

53,200

Check Serina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Serina Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 184.3 K, Interest Expense of 552.3 K or Total Revenue of 53.2 K, as well as many indicators such as Price To Sales Ratio of 691, Dividend Yield of 0.0 or PTB Ratio of 60.39. Serina financial statements analysis is a perfect complement when working with Serina Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Serina Stock
Check out the analysis of Serina Therapeutics Correlation against competitors.
To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.

Serina Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.1 M6.7 M5.1 M
Slightly volatile
Other Current Liabilities1.5 M1.6 M11.9 M
Slightly volatile
Total Current Liabilities2.2 M2.4 M13.5 M
Slightly volatile
Property Plant And Equipment Net654.6 K1 M443.7 K
Slightly volatile
Current Deferred Revenue0.860.9200.6 K
Slightly volatile
Accounts Payable458.6 K744 K361 K
Slightly volatile
Cash3.6 M3.7 M2.2 M
Slightly volatile
Non Current Assets Total1.5 M1 M2.1 M
Slightly volatile
Cash And Short Term Investments3.6 M3.7 M2.2 M
Slightly volatile
Net Receivables48.7 K51.3 K204.3 K
Slightly volatile
Common Stock Shares Outstanding7.7 M7.4 M2.3 M
Slightly volatile
Liabilities And Stockholders Equity5.1 M6.7 M5.1 M
Slightly volatile
Other Stockholder Equity54.3 M45 M55.2 M
Slightly volatile
Total Liabilities5.9 M6.2 M17.9 M
Slightly volatile
Total Current Assets4.9 M5.7 M3.1 M
Slightly volatile
Common Stock95010002.9 K
Slightly volatile
Other Assets36.7 K57.5 K21.5 K
Slightly volatile
Short and Long Term Debt Total254.6 K268 K3.8 M
Slightly volatile
Non Current Liabilities Total3.7 M3.9 M5.2 M
Slightly volatile
Short Term Debt183.3 K193 K1.6 M
Slightly volatile
Intangible Assets953.3 K546.3 K1.7 M
Slightly volatile
Capital Lease Obligations264 K268 K372.7 K
Slightly volatile
Property Plant And Equipment Gross1.4 M1.6 M972.2 K
Slightly volatile
Net Working Capital2.9 M3.3 M1.5 M
Slightly volatile
Capital Surpluse74.8 M45 M96.4 M
Pretty Stable
Cash And Equivalents3.9 M3.7 M1 M
Slightly volatile
Property Plant Equipment838.4 K943.2 K1 M
Slightly volatile

Serina Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization184.3 K194 K618.8 K
Slightly volatile
Interest Expense552.3 K526 K190.9 K
Slightly volatile
Total Revenue53.2 K56 K1.4 M
Slightly volatile
Other Operating Expenses18 M17.1 M12.3 M
Slightly volatile
Research Development3.8 M7.5 M5.9 M
Slightly volatile
Cost Of Revenue184.3 K194 K684.1 K
Slightly volatile
Total Operating Expenses17.8 M16.9 M11.6 M
Pretty Stable
Interest Income2.9 M5.6 M846.2 K
Slightly volatile
Selling General Administrative10.1 M9.6 M2.5 M
Slightly volatile
Selling And Marketing Expenses6 M6.2 M5.5 M
Slightly volatile
Reconciled Depreciation104.1 K194 K53.1 K
Slightly volatile

Serina Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow8 M7.6 M2.8 M
Slightly volatile
Depreciation184.3 K194 K618.8 K
Slightly volatile
Capital Expenditures20.9 K22 K211.3 K
Pretty Stable
Total Cash From Financing Activities13.9 M13.2 M7.6 M
Pretty Stable
End Period Cash Flow2.6 M3.7 M2.1 M
Slightly volatile
Stock Based Compensation2.7 M2.6 M396.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio691658195
Slightly volatile
Days Sales Outstanding5.645.94177
Very volatile
Average Payables202.4 K325.5 K172.9 K
Slightly volatile
Stock Based Compensation To Revenue48.6646.33935.9593
Slightly volatile
Capex To Depreciation0.110.11340.8532
Slightly volatile
EV To Sales627598193
Slightly volatile
Payables Turnover0.250.26082.8714
Slightly volatile
Sales General And Administrative To Revenue18017222.5777
Slightly volatile
Research And Ddevelopement To Revenue14013424.1806
Slightly volatile
Capex To Revenue0.330.39290.1958
Slightly volatile
Cash Per Share0.470.4991.3254
Very volatile
Days Payables Outstanding1.5 K1.4 K447
Slightly volatile
Intangibles To Total Assets0.05540.05830.2995
Very volatile
Current Ratio2.342.3991.357
Slightly volatile
Receivables Turnover47.2949.78188
Pretty Stable
Capex Per Share0.00280.0030.1791
Very volatile
Average Receivables2.8 K2.9 K123.3 K
Slightly volatile
Revenue Per Share0.00720.00761.2242
Slightly volatile
Interest Debt Per Share0.10.10790.8117
Slightly volatile
Debt To Assets0.03790.03990.4374
Pretty Stable
Graham Number2.422.722.9693
Slightly volatile
Operating Cycle5.645.94177
Very volatile
Days Of Payables Outstanding1.5 K1.4 K447
Slightly volatile
Quick Ratio2.342.3991.357
Slightly volatile
Net Income Per E B T0.780.940.9439
Slightly volatile
Cash Ratio1.571.5520.906
Slightly volatile
Days Of Sales Outstanding5.645.94177
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.851.00131.0268
Very volatile
Fixed Asset Turnover0.05840.06156.3341
Slightly volatile
Debt Ratio0.03790.03990.4374
Pretty Stable
Price Sales Ratio691658195
Slightly volatile
Asset Turnover0.00790.00830.4157
Pretty Stable

Serina Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap84.9 M133 M88 M
Pretty Stable
Enterprise Value84.4 M137.7 M88.3 M
Pretty Stable

Serina Fundamental Market Drivers

About Serina Therapeutics Financial Statements

Serina Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Serina Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Serina Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Serina Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.86 
Total Revenue56 K53.2 K
Cost Of Revenue194 K184.3 K
Stock Based Compensation To Revenue 46.34  48.66 
Sales General And Administrative To Revenue 171.86  180.45 
Research And Ddevelopement To Revenue 133.57  140.25 
Capex To Revenue 0.39  0.33 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(304.43)(289.21)

Pair Trading with Serina Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Serina Stock

  0.61EQ Equillium Buyout TrendPairCorr
  0.79RAC Race OncologyPairCorr
  0.83VALN Valneva SE ADRPairCorr

Moving against Serina Stock

  0.85DSGN Design TherapeuticsPairCorr
  0.790P6S Bayer AG NAPairCorr
  0.78DNTH Dianthus TherapeuticsPairCorr
  0.78VCYT VeracytePairCorr
  0.77VERA Vera TherapeuticsPairCorr
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY